Lovelace Biomedical And Environmental Research Institute, Inc.
Doing business as Inhalation Toxicology Research Inst Part of Lovelace Biomedical Research Institute
- UEI
- N1UBCLRAPNG6
- CAGE
- 2D703
- Primary NAICS
- 541380 Testing Laboratories and Services
- SAM.gov registration
- Expired
Company facts
- FY2025 rankings
-
Its parent company, Lovelace Biomedical Research Institute, ranks:
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Tax Exempt)
- Other NAICS codes in SAM.gov
-
- 541511 Custom Computer Programming Services
- 541512 Computer Systems Design Services
- 541513 Computer Facilities Management Services
- 541519 Other Computer Related Services
- 541611 Administrative Management and General Management Consulting Services
- 541612 Human Resources Consulting Services
- 541690 Other Scientific and Technical Consulting Services
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Corporate family
-
-
Parent
Albuquerque, NM
MBT9RXJJ7428
-
Parent
Albuquerque, NM
MBT9RXJJ7428
- SAM.gov registration date
- Website
- lrri.org
- Founded
- 1947
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | -$163,872 |
| FY2024 | -$79,372 |
Contract vehicles
Expired vehicles (16)
- Scientific Equipment and Services
- Professional and Allied Healthcare Staffing Services
- CRO Support for NCATS Medicinal Chemistry for Lead Optimization
- NIAID Preclinical Models of Infectious Diseases 2017-2024
- Assessment of Tobacco Pharmacology and Behavior in Nonclinical Models
- HIV Microbicides and Biomedical Prevention 2016-2021
- CRO Support for NCATS In Vitro and In Vivo Toxicology Studies
- BARDA Biological Animal Model Development 2017-2022
- BARDA Chem and RadNuc Animal Model 2015-2020
- In Vivo Toxicology of Tobacco 2015-2020
- Navy Medicine R&D Support Omnibus III
- BARDA Animal Model Development 2011-2016
- Tobacco Products Pharmacology Study
- PREVENT Toxicology and Pharmacology Testing
- NIAID Animal Models of Infectious Diseases 2010-2017
- HHS Laboratory Testing Services 2010-2015
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Grant subawards
| Prime recipient | Prime award | Amount | Awarded |
|---|---|---|---|
| University Of New Mexico | P20GM130422 | $223,077 | |
| Brigham & Womens Hospital Inc. | R01HL122531 | $90,137 |
Similar vendors
About the company
Lovelace Biomedical and Environmental Research Institute, Inc. (LBERI), doing business as Inhalation Toxicology Research Institute, is a not-for-profit contract research organization that provides preclinical research services to support the development of treatments and cures for respiratory diseases. As a subsidiary of Lovelace Biomedical Research Institute, LBERI leverages over 70 years of expertise in inhalation toxicology, infectious disease modeling, medical countermeasure testing, and translational science.
Through prime and subcontract awards, LBERI performs preclinical efficacy testing of HIV therapeutics, models pharmacodynamics of gene targets related to pain disorders, evaluates medical countermeasures for COVID-19, provides infectious disease modeling services, and conducts research on opioid addiction and withdrawal treatments. Major federal customers include NIH, NIAID, NCATS, BARDA, and Leidos. LBERI has provided these R&D services via cost-plus-fixed-fee and firm-fixed-price delivery orders issued under IDIQ contracts, with no set aside designations.
LBERI also conducts biomedical research on a range of disease states through NIH research project grants. As a prime grantee, LBERI performs studies on neural circuitry and dopamine reward response related to substance abuse. As a subrecipient on NIH awards to universities, LBERI contributes expertise in lung disease modeling, translational science, and biodistribution assays to support research on lung cancer, chronic bronchitis, and nanoparticle inhalation exposure.
Quick answers
Is Lovelace Biomedical And Environmental Research Institute, Inc. registered in SAM.gov?
Lovelace Biomedical And Environmental Research Institute, Inc.'s SAM.gov registration expired on March 14, 2024.
Which contract vehicles does Lovelace Biomedical And Environmental Research Institute, Inc. hold?
Lovelace Biomedical And Environmental Research Institute, Inc. holds a place on 18 federal contract vehicles, including MAS and Preclinical Services for HIV Therapeutics.
How does Lovelace Biomedical And Environmental Research Institute, Inc. rank among federal contractors?
Lovelace Biomedical And Environmental Research Institute, Inc.'s parent company, Lovelace Biomedical Research Institute, ranked #2 in PSC B529, #7 in NAICS 54138 and #27 in PSC B in FY2025.
What is Lovelace Biomedical And Environmental Research Institute, Inc.'s most recent federal award?
Lovelace Biomedical And Environmental Research Institute, Inc.'s most recent federal contract award is The purpose of this task order is to fund the guaranteed minimum amount of the contract (75N93021F00001), from National Institute of Allergy and Infectious Diseases (NIH), on October 15, 2020.
On GovTribe
See Lovelace Biomedical And Environmental Research Institute, Inc.'s full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Federal grant awards
- Subcontracting relationships
- Funding analysis by agency, NAICS and set-aside
- Similar vendors